. . . . . "In the Czech Republic, anagrelide (Thromboreductin) is used according to the recommendations of the Czech Working Group on Myeloproliferative Disorders (CZEMP) for treatment of thrombocythemia associated with Ph-negative myeloproliferative disorders (MPDs). The patient data are collected in the Registry of patients with essential thrombocythemia (ET) and thrombocythemia associated with other MPDs treated with Thromboreductin. At the end of 2012, the Registry contained data on 1,161 patients."@en . "\u00DA\u010Dinnost l\u00E9\u010Dby anagrelidem u nemocn\u00FDch s Ph-negativn\u00EDmi myeloproliferativn\u00EDmi chorobami: ovlivn\u011Bn\u00ED v\u00FDskytu tromb\u00F3zy ve v\u00FDstupech Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bn\u00ED l\u00E9\u010Den\u00E9 Thromboreductinem ke konci roku 2012"@cs . "1"^^ . "Pavl\u00EDk, T." . "Dul\u00ED\u010Dek, P." . . . "[C447FE08D21B]" . "Anagrelid (Thromboreductin*) je v \u010CR pou\u017E\u00EDv\u00E1n dle doporu\u010Den\u00ED \u010Cesk\u00E9 pracovn\u00ED skupiny pro myeloproliferativn\u00ED choroby (CZEMP) k l\u00E9\u010Db\u011B trombocytemie prov\u00E1zej\u00EDc\u00ED Ph-negativn\u00ED chronick\u00E9 myeloproliferace (MPO). \u00DAdaje o nemocn\u00FDch jsou shroma\u017E\u010Fov\u00E1ny v Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bn\u00ED l\u00E9\u010Den\u00FDch Thromboreductinem*(d\u00E1lejen Registr). Jeho v\u00FDstupy byly opakovan\u011B publikov\u00E1ny, naposledy v roce 2010. Zm\u00EDn\u011Bn\u00FD Registr je veden od roku 2001 a od po\u010D\u00E1tku je jeho c\u00EDlem stanoven\u00ED podrobn\u00E9ho klinick\u00E9ho, laboratorn\u00EDho a bezpe\u010Dnostn\u00EDho profilu nemocn\u00FDch. B\u011Bhem sv\u00E9ho u\u017E\u00EDv\u00E1n\u00ED doznala jeho struktura n\u011Bkter\u00FDch zm\u011Bn, kter\u00E9 reaguj\u00ED na v\u00FDstupy z\u00EDsk\u00E1van\u00E9 z dosavadn\u00EDch anal\u00FDz. Tak\u00E9 vypln\u011Bnost datab\u00E1ze se rok od roku zvy\u0161ovala a v n\u011Bkter\u00FDch polo\u017Ek\u00E1ch dos\u00E1hla a\u017E 100 %. Doba sledov\u00E1n\u00ED u nejd\u00E9le sledovan\u00FDch nemocn\u00FDch \u010Din\u00ED 138 m\u011Bs\u00EDc\u016F. V datab\u00E1zi Registru jsou ke konci roku 2012 \u00FAdaje o 1 161 nemocn\u00FDch." . "myeloproliferative disorders; anagrelid (Thromboreductine); thrombosis; patient registry"@en . "Ovesn\u00E1, P." . "Kissov\u00E1, J." . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . . "CZ - \u010Cesk\u00E1 republika" . . "112341" . "Penka, M." . . "Anagrelid (Thromboreductin*) je v \u010CR pou\u017E\u00EDv\u00E1n dle doporu\u010Den\u00ED \u010Cesk\u00E9 pracovn\u00ED skupiny pro myeloproliferativn\u00ED choroby (CZEMP) k l\u00E9\u010Db\u011B trombocytemie prov\u00E1zej\u00EDc\u00ED Ph-negativn\u00ED chronick\u00E9 myeloproliferace (MPO). \u00DAdaje o nemocn\u00FDch jsou shroma\u017E\u010Fov\u00E1ny v Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bn\u00ED l\u00E9\u010Den\u00FDch Thromboreductinem*(d\u00E1lejen Registr). Jeho v\u00FDstupy byly opakovan\u011B publikov\u00E1ny, naposledy v roce 2010. Zm\u00EDn\u011Bn\u00FD Registr je veden od roku 2001 a od po\u010D\u00E1tku je jeho c\u00EDlem stanoven\u00ED podrobn\u00E9ho klinick\u00E9ho, laboratorn\u00EDho a bezpe\u010Dnostn\u00EDho profilu nemocn\u00FDch. B\u011Bhem sv\u00E9ho u\u017E\u00EDv\u00E1n\u00ED doznala jeho struktura n\u011Bkter\u00FDch zm\u011Bn, kter\u00E9 reaguj\u00ED na v\u00FDstupy z\u00EDsk\u00E1van\u00E9 z dosavadn\u00EDch anal\u00FDz. Tak\u00E9 vypln\u011Bnost datab\u00E1ze se rok od roku zvy\u0161ovala a v n\u011Bkter\u00FDch polo\u017Ek\u00E1ch dos\u00E1hla a\u017E 100 %. Doba sledov\u00E1n\u00ED u nejd\u00E9le sledovan\u00FDch nemocn\u00FDch \u010Din\u00ED 138 m\u011Bs\u00EDc\u016F. V datab\u00E1zi Registru jsou ke konci roku 2012 \u00FAdaje o 1 161 nemocn\u00FDch."@cs . "RIV/00023736:_____/13:00010720" . "http://www.prolekare.cz/vnitrni-lekarstvi-clanek/ucinnost-lecby-anagrelidem-u-nemocnych-s-ph-negativnimi-myeloproliferativnimi-chorobami-ovlivneni-vyskytu-tro-40886" . "16"^^ . "0042-773X" . . "The effectiveness of anagrelide treatment in patients with Ph-negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative disases trated with Thromboreductin to the end of 2012"@en . "Schwarz, Ji\u0159\u00ED" . . "59" . "V" . "RIV/00023736:_____/13:00010720!RIV14-MZ0-00023736" . . "Posp\u00ED\u0161ilov\u00E1, D." . . "\u010Cerv\u00EDnek, L." . "8"^^ . "The effectiveness of anagrelide treatment in patients with Ph-negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative disases trated with Thromboreductin to the end of 2012"@en . . "\u00DA\u010Dinnost l\u00E9\u010Dby anagrelidem u nemocn\u00FDch s Ph-negativn\u00EDmi myeloproliferativn\u00EDmi chorobami: ovlivn\u011Bn\u00ED v\u00FDskytu tromb\u00F3zy ve v\u00FDstupech Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bn\u00ED l\u00E9\u010Den\u00E9 Thromboreductinem ke konci roku 2012" . "\u00DA\u010Dinnost l\u00E9\u010Dby anagrelidem u nemocn\u00FDch s Ph-negativn\u00EDmi myeloproliferativn\u00EDmi chorobami: ovlivn\u011Bn\u00ED v\u00FDskytu tromb\u00F3zy ve v\u00FDstupech Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bn\u00ED l\u00E9\u010Den\u00E9 Thromboreductinem ke konci roku 2012" . "\u00DA\u010Dinnost l\u00E9\u010Dby anagrelidem u nemocn\u00FDch s Ph-negativn\u00EDmi myeloproliferativn\u00EDmi chorobami: ovlivn\u011Bn\u00ED v\u00FDskytu tromb\u00F3zy ve v\u00FDstupech Registru pacient\u016F s diagn\u00F3zou esenci\u00E1ln\u00ED trombocytemie a trombocytemie prov\u00E1zej\u00EDc\u00ED jin\u00E9 myeloproliferativn\u00ED onemocn\u011Bn\u00ED l\u00E9\u010Den\u00E9 Thromboreductinem ke konci roku 2012"@cs . . "6" .